TTRX · NASDAQ · Biotechnology

Turn Therapeutics (TTRX)

Develops GX-03 for skin disease while licensing medical-device products.

$14.28
vs last close−1.01 (−6.63%)

Something off on this page? Send us feedback.

Next report
Nov 12, 26
estimated · in 50 days
EPS estimate
−$0.09
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Sep '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.09−$0.07$0.01−$0.03−$0.20Pending
Estimate−$0.05−$0.05−$0.02−$0.02−$0.09
Surprise−37.3%+118.6%−50.0%−900.0%

RevenueReportedEstimate

Sep '25Nov '25Mar '26May '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Dec 2028−$0.05
Sep 2028−$0.04
Jun 2028−$0.04
Mar 2028−$0.04
Dec 2027−$0.12
Sep 2027−$0.08
Jun 2027−$0.11
Mar 2027−$0.05
Dec 2026−$0.08
Nov 2026−$0.09
Aug 2026−$0.02−$0.20−900.0%
May 2026−$0.02−$0.03−50.0%
Mar 2026−$0.05$0.01+118.6%
Nov 2025−$0.05−$0.07−37.3%
Sep 2025
Jun 2025

The latest year is open to everyone — the 2 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2028−$0.05$0
Sep 2028−$0.04$0
Jun 2028−$0.04$0
Mar 2028−$0.04$0
Dec 2027−$0.12$0
Sep 2027−$0.08$0
Jun 2027−$0.11$0
Mar 2027−$0.05$0
Dec 2026−$0.08$500.0K
Nov 12, 2026−$0.09$0
Aug 13, 2026−$0.02−$0.20−900.0%−2.9%
May 11, 2026−$0.02−$0.03−50.0%+2.4%
Mar 31, 2026−$0.05$0.01+118.6%−2.5%
Nov 13, 2025−$0.05−$0.07−37.3%−7.1%
Sep 2, 2025
Jun 27, 2025

The latest year is open to everyone — the 2 quarters behind it read with an account.